VIEMED HEALTHCARE, INC. (VMD) research
VIEMED HEALTHCARE, INC.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $9.13
- As of
VIEMED HEALTHCARE, INC. (VMD): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-20.
As of . Source: SEC EDGAR filings for VMD. Method and limitations.
Share the VMD intelligence card
See the full VMD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VMD on one page. Preview it with sample data, then open it live with a free account.
Preview the VMD dossierActive signals for VMD
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +287% to VMD (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 42.2%, EPS $0.07 vs $0.1212 estimate
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +58% to VMD (2026Q1)
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 10.8% - EPS $0.14 vs $0.1263 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 34.0% - EPS $0.06 vs $0.0909 estimate
FREE, NO ACCOUNT
Every signal on VMD, as it fires
New filings, 13F moves and cross asset signals on VMD land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VMD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 92663R105 · 2026Q2 | $5M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 92663R105 · 2026Q2 | $4.9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 92663R105 · 2026Q2 | $2.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 92663R105 · 2026Q2 | $1.8M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 92663R105 · 2026Q2 | $592K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VMD
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
VMD against its peers
VMD's operating margin of 8.5% ranks in the 89th percentile of 21 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-06-30.
| Metric | VMD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 270M USD | 85.2M USD | 84 | 21 |
| Gross margin | 57.5% | 58.7% | 50 | 20 |
| Operating margin | 8.5% | -33.7% | 89 | 21 |
| Net margin | 5.5% | -28.5% | 84 | 21 |
| Return on equity | 10.6% | -41.1% | 83 | 20 |
| P / E | 24.7x | 27.0x | 42 | 5 |
Peers (22): CLPT, QSI, CV, RCEL, OFIX, CATX, LAB, TMCI, TLSI, NPCE, INFU, TCMD, ELMD, SENS, MASS, DCTH, KIDS, SSII, STIM, EBRCZ, QTRX, QDEL. Left out: MOBI (no annual filing), BWAY (period gap), PROF (no annual filing). Fiscal periods ending between 2025-12-28 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (VMD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more VMD signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to VMDand get the insider, 13F, options, and confluence read in one view.